Strategies for Enhancing Monoclonal Antibody Accumulation in Plant Cell and Organ Cultures

2001 ◽  
Vol 17 (6) ◽  
pp. 979-992 ◽  
Author(s):  
J.M. Sharp ◽  
P.M. Doran
2013 ◽  
pp. 2761-2796 ◽  
Author(s):  
Mercedes Bonfill ◽  
Sonia Malik ◽  
M. Hossein Mirjalili ◽  
Marta Goleniowski ◽  
Rosa Cusido ◽  
...  

2020 ◽  
Vol 21 (3) ◽  
pp. 716 ◽  
Author(s):  
Thanh-Tam Ho ◽  
Hosakatte Niranjana Murthy ◽  
So-Young Park

Recently, plant secondary metabolites are considered as important sources of pharmaceuticals, food additives, flavours, cosmetics, and other industrial products. The accumulation of secondary metabolites in plant cell and organ cultures often occurs when cultures are subjected to varied kinds of stresses including elicitors or signal molecules. Application of exogenous jasmonic acid (JA) and methyl jasmonate (MJ) is responsible for the induction of reactive oxygen species (ROS) and subsequent defence mechanisms in cultured cells and organs. It is also responsible for the induction of signal transduction, the expression of many defence genes followed by the accumulation of secondary metabolites. In this review, the application of exogenous MJ elicitation strategies on the induction of defence mechanism and secondary metabolite accumulation in cell and organ cultures is introduced and discussed. The information presented here is useful for efficient large-scale production of plant secondary metabolites by the plant cell and organ cultures.


2015 ◽  
Vol 176 ◽  
pp. 426-432 ◽  
Author(s):  
Hosakatte Niranjana Murthy ◽  
Milen I. Georgiev ◽  
So-Young Park ◽  
Vijayalaxmi S. Dandin ◽  
Kee-Yoeup Paek

Author(s):  
Tuncay Çalışkan ◽  
Rüştü Hatipoğlu ◽  
Saliha Kırıcı

Plant secondary metabolites are a group of organic compounds produced by plants to interact with biotic and abiotic factors and for the establishment of defence mechanism. Secondary metabolites are classified based on their biosynthetic origin and chemical structure. They have been used as pharmaceutical, agrochemical, flavours, fragrances, colours and food additives. Secondary metabolites are traditionally produced from the native grown or field grown plants. However, this conventional approach has some disadvantages such as low yield, instability of secondary metabolite contents of the plants due to geographical, seasonal and environmental variations, need for land and heavy labour to grow plants. Therefore, plant cell and organ cultures have emerged as an alternative to plant growing under field conditions for secondary metabolite production. In this literature review, present state of secondary metabolite production through plant cell and organ cultures, its problems as well as solutions of the problems were discussed.


2018 ◽  
Vol 25 (30) ◽  
pp. 3577-3596 ◽  
Author(s):  
Diego Hidalgo ◽  
Raul Sanchez ◽  
Liliana Lalaleo ◽  
Mercedes Bonfill ◽  
Purificacion Corchete ◽  
...  

Background: Plant biofactories are biotechnological platforms based on plant cell and organ cultures used for the production of pharmaceuticals and biopharmaceuticals, although to date only a few of these systems have successfully been implemented at an industrial level. Metabolic engineering is possibly the most straightforward strategy to boost pharmaceutical production in plant biofactories, but social opposition to the use of GMOs means empirical approaches are still being used. <P><P> Plant secondary metabolism involves thousands of different enzymes, some of which catalyze specific reactions, giving one product from a particular substrate, whereas others can yield multiple products from the same substrate. This trait opens plant cell biofactories to new applications, in which the natural metabolic machinery of plants can be harnessed for the bioconversion of phytochemicals or even the production of new bioactive compounds. Synthetic biological pipelines involving the bioconversion of natural substrates into products with a high market value may be established by the heterologous expression of target metabolic genes in model plants. <P><P> Objective: To summarize the state of the art of plant biofactories and their applications for the pipeline production of cosme-, pharma- and biopharmaceuticals. <P><P> Results: In order to demonstrate the great potential of plant biofactories for multiple applications in the biotechnological production of pharmaceuticals and biopharmaceuticals, this review broadly covers the following: plant biofactories based on cell and hairy root cultures; secondary metabolite production; biotransformation reactions; metabolic engineering tools applied in plant biofactories; and biopharmaceutical production.


2003 ◽  
Vol 185 (8) ◽  
pp. 2538-2547 ◽  
Author(s):  
Philip F. Markham ◽  
Anna Kanci ◽  
György Czifra ◽  
Bo Sundquist ◽  
Peter Hains ◽  
...  

ABSTRACT While the genomes of a number of Mycoplasma species have been fully determined, there has been limited characterization of which genes are essential. The surface protein (p47) identified by monoclonal antibody B3 is the basis for an enzyme-linked immunosorbent assay for serological detection of Mycoplasma gallisepticum infection and appears to be constitutively expressed. Its gene was cloned, and the DNA sequence was determined. Subsequent analysis of the p47 amino acid sequence and searches of DNA databases found homologous gene sequences in the genomes of M. pneumoniae and M. genitalium and identity with a gene family in Ureaplasma urealyticum and genes in M. agalactiae and M. fermentans. The proteins encoded by these genes were found to belong to a family of basic membrane proteins (BMP) that are found in a wide range of bacteria, including a number of pathogens. Several of the BMP family members, including p47, contain selective lipoprotein-associated motifs that are found in macrophage-activating lipoprotein 404 of M. fermentans and lipoprotein P48 of M. agalactiae. The p47 gene was predicted to encode a 59-kDa peptide, but affinity-purified p47 had a molecular mass of approximately 47 kDa, as determined by polyacrylamide gel analysis. Analysis of native and recombinant p47 by mass peptide fingerprinting revealed the absence of the carboxyl end of the protein encoded by the p47 gene in native p47, which would account for the difference seen in the predicted and measured molecular weights and indicated posttranslational cleavage of the lipoprotein at its carboxyl end. A DNA construct containing the p47 gene interrupted by the gene encoding tetracycline resistance was used to transform M. gallisepticum cells. A tetracycline-resistant mycoplasma clone, P2, contained the construct inserted within the genomic p47 gene, with crossovers occurring between 73 bp upstream and 304 bp downstream of the inserted tetracycline resistance gene. The absence of p47 protein in clone P2 was determined by the lack of reactivity with rabbit anti-p47 sera or monoclonal antibody B3 in Western blots of whole-cell proteins. There was no difference between the p47− mutant and wild-type M. gallisepticum in pathogenicity in chicken tracheal organ cultures. Thus, p47, although homologous to genes that occur in many prokaryotes, is not essential for growth in vitro or for attachment and the initial stages of pathogenesis in chickens.


Sign in / Sign up

Export Citation Format

Share Document